Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-adapted therapy in advanced Hodgkin Lymphoma
NCT00795613Phase 2Unknown
- Sponsor
- Ospedale Santa Croce e Carle
- Start
- Jun 2008
- Primary completion
- Nov 2014
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of rituximab in Hodgkin lymphoma (HL), sponsored by Ospedale Santa Croce e Carle. Status: unknown.
02
Drugs
rituximab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00795613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00795613.